Exeter company secures 870k awards for AI medical technology


An Exeter-based company which uses sophisticated mathematical modelling to help develop treatment plans for people with epilepsy, has received two prestigious UK government funded awards.

Neuronostics, a spin-out from the University of Exeter, has received funding worth a total of almost £900,000 to develop their patented BioEP technology - a revolutionary biomarker of the susceptibility to seizures in the human brain, informed by clinical EEG recordings - for both clinical and at-home use.

This funding is part of a £50M package of support for artificial intelligence in health and care by the National Institute for Health Research (NIHR), announced today (September 8th 2020). For both projects, Neuronostics will be involving those with lived experience of epilepsy and medical staff involved in the support and treatment of people with epilepsy. Anyone interested in becoming involved is encouraged to get in touch via info@neuronostics.com for more information.

Professor John Terry, co-founder of Neuronostics and Interdisciplinary Professorial Fellow at the University of Birmingham, said: “I’m delighted that we have secured these two awards.  They will enable us to accelerate our product development, and importantly to clinically validate the performance of the BioEP seizure risk score.”


Back to article list